34results about "CD45" patented technology

The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising : (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, and wherein each of the first and second CARs is an activating CAR comprising an activating endodomain.

In one embodiment, the present disclosure provides an engineered cell having a first chimeric antigen receptor polypeptide including a first antigen recognition domain, a first signal peptide, a firsthinge region, a first transmembrane domain, a first co- stimulatory domain, and a first signaling domain; and a second chimeric antigen receptor polypeptide including a second antigen recognition domain, a second signal peptide, a second hinge region, a second transmembrane domain, a second co- stimulatory domain, and a second signaling domain, wherein the first antigen recognition domain is different from the second antigen recognition domain.

The present invention relates to an anti-L1CAM antibody specifically binding to L1CAM antigen or an antigen-binding fragment thereof, a chimeric antigen receptor comprising the same, and uses thereof. The anti-L1CAM antibody or the antigen-binding fragment of the present invention is excellent in specificity and affinity to L1CAM and thus may be used in the treatment and diagnosis of cancers related to high expression of L1CAM and diseases related to inflammatory disorders. In particular, when the chimeric antigen receptor comprising the anti-L1CAM antibody of the present invention is expressed in effector cells such as T lymphocytes, the chimeric antigen receptor may be effectively used as immunotherapy for cancers related to L1CAM and inflammatory disorders.

The present disclosure features, at least in part, methods for conserving cell function, immune cell function, e.g., after one or more cycles of freezing and / or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.

The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) which comprises an antigen binding domain and an intracellular signalling domain; (ii) a membrane tetheringcomponent (MTC) which comprises a first dimerization domain; and (Hi) a signal-dampening component (SDC) comprising a signal-dampening domain (SDD) and a second dimerization domain which specificallybinds the first dimerisation domain of the membrane-tethering component. Dimerisation between the MTC and SDC may be controllable with an agent, meaning that the agent can be used to control CAR-mediated cell signalling.

The present invention provides a nucleic acid construct comprising the following structure: A-X-B in which A is nucleic acid sequence encoding a first polypeptide which comprises a first signal peptide; B is nucleic acid sequence encoding a second polypeptide which comprises a second signal peptide and X is a nucleic acid sequence which encodes a cleavage site, wherein the first signal peptide orthe second signal peptide comprises one or more mutation(s) such that it has fewer hydrophobic amino acids.

The present invention provides a preparation method and application of enhanced Slit2CAR-T and CAT-NK cells, the enhanced CAR-T and CAT-NK cells are respectively T cells and NK cells containing enhanced CAR chimeric antigen receptors , wherein the enhanced CAR chimeric antigen receptor includes an extracellular domain capable of binding antigen, a transmembrane domain, an intracellular immune costimulatory molecule, an internal ribosome entry site IRES and HAC-HSA in series; wherein the extracellular domain Includes the D2 domain of the Slit2 protein. The enhanced CAR-T cells and enhanced CAR-NK cells of the present invention can block the PDL-1 inhibitory signal, enhance the killing activity of CAR-immune cells, and activate tumor-infiltrating immune cells; the enhanced CAR-immune cells can be used as Cellular medicine is used in the treatment of tumor diseases, so that the modified immune cells can specifically recognize and kill tumors, and have more efficient tumor killing activity.